Endostatin plus interferon-α2b therapy for metastatic melanoma: A novel combination of antiangiogenic and immunomodulatory agents

Melanoma Research

Volumn 17, Issue 3, 2007, Pages 193-200

  Moschos, Stergios J ^a   Odoux, Christine ^a   Land, Stephanie R ^b   Agarwala, Sanjiv ^a   Friedland, David ^a   Volker, Kirk M ^c   Sidor, Carolyn ^c   Wong, Michael ^d   Kirkwood, John M ^a,e  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c EntreMed   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e Department of Medicine ^*  (United States)

Author keywords

Antiangiogenesis; Circulating endothelial cells; Endostatin; Interferon 2b

Indexed keywords

ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; ENDOSTATIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOMODULATING AGENT;

ADULT; AGED; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTIBODY TITER; APPLICATION SITE REACTION; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENDOTHELIUM CELL; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; NEUROTOXICITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKIN METASTASIS; THERAPY EFFECT; TREATMENT RESPONSE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; ENDOSTATINS; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PILOT PROJECTS; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34249011849     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3281ad91a3     Document Type: Article

References (35)

1. Moschos SJ, Konstantinopoulos PA, Kirkwood JM. Melanoma. Cancer Chemother Biol Response Modif 2005; 22:563-590.
2. Moschos S, Varanasi S, Kirkwood JM. Interferons in the treatment of solid tumors. Cancer Treat Res 2005; 126:207-241.
3. Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science 1980; 208:516-518.
4. Von Marschall Z, Scholz A, Cramer T, Schafer G, Schimer M, Oberg K, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003; 95:437-448.
5. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A 1995; 92:4562-4566.
6. Naldini A, Pucci A, Bernini C, Carraro F. Regulation of angiogenesis by Th1- and Th2-type cytokines. Curr Pharm Des 2003; 9:511-519.
7. Legha SS. The role of interferon alfa in the treatment of metastatic melanoma. Semin Oncol 1997; 24:S24-S31.
8. Kirkwood JM, Ernstoff MS, Davis CA, Reiss M, Ferraresi R, Rudnick SA. Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med 1985; 103:32-36.
9. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390:404-407.
10. Benezra R, Rafii S. Endostatin's endpoints - Deciphering the endostatin antiangiogenic pathway. Cancer Cell 2004; 5:205-206.
11. Eder JP Jr, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002; 20:3772-3784.
12. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J. Clin Oncol 2002; 20:3792-3803.
13. Thomas JP, Arzoomanian RZ, Alberti D, Feierabend C, Binger K, Tutsch KD, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003; 21:223-231.
14. Li M, Huang X, Zhu Z,Wong M,Watkins S, Zhao O, et al. Immune response against 3LL Lewis lung carcinoma potentiates the therapeutic efficacy of endostatin. J Immunother 2001; 24:472-481.
15. Ozawa S, Shinohara H, Kanayama HO. Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha. Neoplasia 2001; 3:154-164.
16. Carson WE, Biber J, Shah N, Reddy K, Kefauver C, Leming PD, et al. A phase II trial of a recombinant humanized monoclonal antivascular endothelial growth factor (VEGF) antibody in patients with malignant melanoma (abstract 2873). Proc Am Soc Clin Oncol 2003; 22:715.
17. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994; 86:356-361.
18. Feldman AL, Tamarkin L, Paciotti GF, Simpson BW, Linehan WM, Yang JC, et al. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res 2000; 6:4628-4634.
19. Solovey AN, Gui L, Chang L, Enenstein J, Browne PV, Hebbel RP. Identification and functional assessment of endothelial P1H12. J Lab Clin Med 2001; 138:322-331.
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
21. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10:1-10.
22. Soutter AD, Nguyen M, Watanabe H, Folkman J. Basic fibroblast growth factor secreted by an animal tumor is detectable in urine. Cancer Res 1993; 53:5297-5299.
23. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001; 97:3658-3661.
24. Schuch G, Heymach JV, Nomi M, Machluf M, Force J, Atala A, et al. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res 2003; 63:8345-8350.
25. Hernberg M, Virkkunen P, Bono P, Ahtinen H, Maenpaa H, Joensuu H. Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J Clin Oncol 2003; 21:3770-3776.
26. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. Eastern Cooperative Oncology Group. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004; 10:1670-1677.
27. Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E, et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001; 61:7669-7674.
28. Hansma AH, Hoekman K, Broxterman HJ, Kievit E, Horst I, Boven E, et al. A phase I study of rh-Endostatin: continuous intravenous (i.v.) followed by subcutaneous (s.c.) administration (abstract 436). Proc Am Soc Clin Oncol 2002; 21:110a.
29. Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O'Reilly M, et al. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res 2004; 10:33-42.
30. Kulke M, Bergsland E, Ryan DP, Clark JW, Enzinger PC, Michelini A, et al. A phase II, open-label, safety, pharmacokinetic, and efficacy study of recombinant human endostatin in patients with advanced neuroendocrine tumors (abstract 958). Proc Am Soc Clin Oncol 2003; 22:239.
31. Hersey P, Sosman J, O'Day S, Richards J, Bedikian A, Gonzalez R, et al. A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, ±dacarbazine (DTIC) in patients with metastatic melanoma (abstract 7507). Proc Am Soc Clin Oncol 2005; 23:711S.
32. Dinney CP, Bielenberg DR, Perrotte P, Reich R, Eve BY, Bucana DC, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998; 58:808-814.
33. Vermeulen PB, Dirix LY, Martin M, Lemmens J, Van Oosterom AT. Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon alfa-2b. J Natl Cancer Inst 1997; 89:1316-1317.
34. Nilsson A, Janson ET, Eriksson B, Larsson A. Levels of angiogenic peptides in sera from patients with carcinoid tumours during alpha-interferon treatment. Anticancer Res 2001; 21:4087-4090.
35. Heymach J, Kulke MH, Fuchs CS, Force J, Connors S, Sidor C, et al. Circulating endothelial cells as a surrogate marker of antiangiogenic activity in patients treated with endostatin (abstract 979). Proc Am Soc Clin Oncol 2003; 22:244.